Comparison Between DSQIID Total / Sub-item Scores and Plasma P-tau Elevation in Adults with Down's Syndrome

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Dec 9

PMID 39652530

Authors

Makiko Shinomoto

Chisen Takeuchi

Harutsugu Tatebe

Fukiko Kitani-Morii

Takuma Ohmichi

Yuzo Fujino

Kanako Menjo

Naoto Terada

Miho Osako

Yoko Mochizuki

Satoshi Teramukai

Takahiko Tokuda

Toshiki Mizuno

Takashi Kasai

Affiliations

Soon will be listed here.

Abstract

The Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID) is an appropriate screening tool for detecting dementia in Down's syndrome patients. However, whether this questionnaire reflects the neuropsychiatric signs of biomarker-confirmed Alzheimer's disease in DS (DS-AD) remains unknown. To address this issue, we compared the plasma phosphorylated tau (P181tau: p-tau) level of a representative AD biomarker with the total score and each sub-score of the DSQIID. The DSQIID was completed by 43 of the 56 individuals enrolled in the study. The DSQIID total scores tended to be positively associated with age, and some sub-scores increased in an age-dependent manner. DSQIID total scores and some sub-scores were also positively correlated with plasma p-tau levels, while all significant correlations disappeared after adjusting for age. Moreover, one sub-score appeared to have a significant negative correlation with plasma p-tau levels after adjusting for age. The DSQIID likely reflects age-associated behavioral changes in patients with DS. Meanwhile, their scores did not correlate with plasma p-tau after adjusting for age, suggesting that there might be room for improvement in the DSQIID for detecting DS-AD.

References

Annus T, Wilson L, Hong Y, Acosta-Cabronero J, Fryer T, Cardenas-Blanco A . The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement. 2015; 12(5):538-45. PMC: 4867786. DOI: 10.1016/j.jalz.2015.07.490. View

Mielke M, Dage J, Frank R, Algeciras-Schimnich A, Knopman D, Lowe V . Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022; 28(7):1398-1405. PMC: 9329262. DOI: 10.1038/s41591-022-01822-2. View

Lautarescu B, Holland A, Zaman S . The Early Presentation of Dementia in People with Down Syndrome: a Systematic Review of Longitudinal Studies. Neuropsychol Rev. 2017; 27(1):31-45. PMC: 5359367. DOI: 10.1007/s11065-017-9341-9. View

De Simone R, Puig X, Gelisse P, Crespel A, Genton P . Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer's disease in Down syndrome. Seizure. 2010; 19(7):383-9. DOI: 10.1016/j.seizure.2010.04.008. View

Mann D . The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev. 1988; 43(2):99-136. DOI: 10.1016/0047-6374(88)90041-3. View

Kasai T, Tatebe H, Kondo M, Ishii R, Ohmichi T, Yeung W . Increased levels of plasma total tau in adult Down syndrome. PLoS One. 2017; 12(11):e0188802. PMC: 5708632. DOI: 10.1371/journal.pone.0188802. View

Kamboh M, Ferrell R, Kottke B . Genetic studies of human apolipoproteins. V. A novel rapid procedure to screen apolipoprotein E polymorphism. J Lipid Res. 1988; 29(11):1535-43. View

Thijssen E, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L . Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020; 26(3):387-397. PMC: 7101073. DOI: 10.1038/s41591-020-0762-2. View

van Dyck C, Swanson C, Aisen P, Bateman R, Chen C, Gee M . Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2022; 388(1):9-21. DOI: 10.1056/NEJMoa2212948. View

10.

Moran J, Rafii M, Keller S, Singh B, Janicki M . The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities. Mayo Clin Proc. 2013; 88(8):831-40. DOI: 10.1016/j.mayocp.2013.04.024. View

11.

Jack Jr C, Scott Andrews J, Beach T, Buracchio T, Dunn B, Graf A . Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024; 20(8):5143-5169. PMC: 11350039. DOI: 10.1002/alz.13859. View

12.

Lleo A, Zetterberg H, Pegueroles J, Karikari T, Carmona-Iragui M, Ashton N . Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. Nat Commun. 2021; 12(1):4304. PMC: 8280160. DOI: 10.1038/s41467-021-24319-x. View

13.

Lott I, Head E . Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019; 15(3):135-147. PMC: 8061428. DOI: 10.1038/s41582-018-0132-6. View

14.

Rafii M . Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome?. Alzheimers Res Ther. 2014; 6(5-8):60. PMC: 4255529. DOI: 10.1186/s13195-014-0060-7. View

15.

Mann D . Cerebral amyloidosis, ageing and Alzheimer's disease; a contribution from studies on Down's syndrome. Neurobiol Aging. 1989; 10(5):397-9; discussion 412-4. DOI: 10.1016/0197-4580(89)90073-0. View

16.

Deb S, Hare M, Prior L, Bhaumik S . Dementia screening questionnaire for individuals with intellectual disabilities. Br J Psychiatry. 2007; 190:440-4. DOI: 10.1192/bjp.bp.106.024984. View

17.

Wiseman F, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz V . A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015; 16(9):564-74. PMC: 4678594. DOI: 10.1038/nrn3983. View

18.

Zeilinger E, Zrnic Novakovic I, Komenda S, Franken F, Sobisch M, Mayer A . Informant-based assessment instruments for dementia in people with intellectual disability: A systematic review and standardised evaluation. Res Dev Disabil. 2021; 121:104148. DOI: 10.1016/j.ridd.2021.104148. View

19.

Chen S, Huang Y, Shen X, Guo Y, Tan L, Dong Q . Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease. Transl Psychiatry. 2021; 11(1):356. PMC: 8197760. DOI: 10.1038/s41398-021-01476-7. View

20.

McCarron M, McCallion P, Reilly E, Dunne P, Carroll R, Mulryan N . A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect Disabil Res. 2017; 61(9):843-852. DOI: 10.1111/jir.12390. View